Humacyte, Inc.

Equities

HUMA

US44486Q1031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
7.27 ^USD	-0.68%		-2.81%	+155.99%

03/06	Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing	MT
30/05	Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	CI

Humacyte, Inc. Adds New Board Members

November 12, 2021 at 06:00 pm IST

Humacyte, Inc. added new board members Gordon M. Binder, Dr. Emery N. Brown, Michael T. Constantino, Todd M. Pope, Rajiv Shukla and Dr. Susan Windham-Bannister. Prior legacy Humacyte board members continuing their service include Dr. Jeff Lawson, Max Wallace, Brady Dougan, Dr. Laura Niklason and Kathleen Sebelius, who was also appointed board chair.

Latest news about Humacyte, Inc.

Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing	04/06	MT
Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30/05	CI
Certain Warrants of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30/05	CI
Certain Stock Options of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30/05	CI
Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024	10/05
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Transcript : Humacyte, Inc. - Special Call	28/03
Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024	22/03
Interest Rate, Monetary Policy Views Lift Wall Street Pre-Bell; Asia Mixed, Europe Up	22/03	MT
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/03	CI
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating	08/03	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01/03	MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	01/03	MT
Humacyte Prices $40.2 Million Share Offering	01/03	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	10/02	MT
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment	10/02	DJ
Sector Update: Health Care Stocks Mixed in Afternoon Trading	10/02	MT
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	09/02	MT
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma	09/02	DJ
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	09/02	CI
Humacyte Seeks FDA Approval of Bioengineered Tissue for Treatment of Vascular Injuries	12/12	MT
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	12/12	CI
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6	11/12	MT

Chart Humacyte, Inc.

Duration

Period

More charts

Company Profile

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Companyâs scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Tissue Engineering and Regenerative Medicine Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.27 USD

Average target price

8 USD

Spread / Average Target

+10.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HUMACYTE, INC.	+155.99%	866M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research